



HCC UK Referrers Day 2024

Date: Wed 2nd October 2024, Liver Cancer Awareness Month Location: Online educational meeting

Course objective: up-to-date clinical guidance for hepatologists, gastroenterologists, oncologists, specialist nurses and allied healthcare professionals on which treatments your patients with HCC are eligible for, who to refer for liver transplantation, vital roles of the MDT, and current clinical trials recruiting nationally.

Course Programme:

Course Introduction	Dr Nekisa Zakeri &	& Dr Aileen Marshall
	I future plans?	Dr Hamish Innes
Coffee Break (20 mins)		
Which treatments are my patients with I SIRT 	-	Part 2 Dr Peter Littler Prof Tim Meyer
 (20mins per talk and 10mins for Q&As part Patient selection and clinical 	<i>el discussion at en</i> al outcomes	d) Dr Abid Suddle Prof Shishir Shetty
Lunch break (45 mins)		
	C CNS team	Ms Sarah Selemani
		Prof Dhiraj Tripathi Ms Jill Johnson Dr Ahmed Elsharkawy
What does the future of HCC manageme	ent look like?	Prof Helen Reeves
Closing statements		
	Which treatments are my patients with I (15mins per talk and 15mins for Q&As part Ablation Surgical Resection TAE/TACE SABR Coffee Break (20 mins) ross Which treatments are my patients with I SIRT Systemic therapy & clinical Who should we refer for liver transplant (20mins per talk and 10mins for Q&As part Patient selection and clinica Downstaging and bridging Lunch break (45 mins) a Zakeri Current roles & future expansion of HCC Medical optimisation of the patient with Varices assessment/manage Nutrition and HCC Viral hepatitis and HCC What does the future of HCC management	 Marshall HCC Surveillance – where are we at and future plans? Which treatments are my patients with HCC eligible for? If (15mins per talk and 15mins for Q&As panel discussion at end a Ablation Surgical Resection TAE/TACE SABR Coffee Break (20 mins) ross Which treatments are my patients with HCC eligible for? If SIRT Systemic therapy & clinical trials Who should we refer for liver transplantation for HCC? (20mins per talk and 10mins for Q&As panel discussion at end Patient selection and clinical outcomes Downstaging and bridging treatment Lunch break (45 mins) a Zakeri Current roles & future expansion of HCC CNS team Medical optimisation of the patient with HCC Nutrition and HCC Viral hepatitis and HCC

BASL would like to that the following pharmaceutical companies for their support of this meeting. The sponsors have had no influence or input into the programme, agenda or content of the meeting.



